Sanofi - ADR (SNY): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNY POWR Grades
- Stability is the dimension where SNY ranks best; there it ranks ahead of 96.36% of US stocks.
- SNY's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
- SNY ranks lowest in Momentum; there it ranks in the 11th percentile.
SNY Stock Summary
- With a market capitalization of $128,621,016,471, Sanofi has a greater market value than 98.13% of US stocks.
- Over the past twelve months, SNY has reported earnings growth of 138.44%, putting it ahead of 87.37% of US stocks in our set.
- The volatility of Sanofi's share price is greater than that of merely 1.8% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Sanofi are TGT, IBM, RTX, AMAT, and MMM.
- SNY's SEC filings can be seen here. And to visit Sanofi's official web site, go to www.sanofi.com.
SNY Stock Price Chart Interactive Chart >
SNY Price/Volume Stats
| Current price | $51.86 | 52-week high | $54.26 |
| Prev. close | $51.42 | 52-week low | $44.76 |
| Day low | $51.50 | Volume | 2,024,600 |
| Day high | $52.15 | Avg. volume | 1,908,802 |
| 50-day MA | $52.62 | Dividend yield | 2.64% |
| 200-day MA | $50.01 | Market Cap | 130.58B |
Sanofi - ADR (SNY) Company Bio
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
SNY Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $51.86 | $38.04 | -29% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Sanofi. To summarize, we found that Sanofi ranked in the 45th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for SNY, they are:
- In the past 5 years, Sanofi has a compound free cash flow growth rate of 0%; that's higher than only 19.53% of free cash flow generating stocks in the Healthcare sector.
- Sanofi's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 7.53% of tickers in our DCF set.
- SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than only 7.53% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -31% |
| 1% | -30% |
| 2% | -29% |
| 3% | -29% |
| 4% | -28% |
| 5% | -27% |
MCK, ADUS, INFU, REGN, and ABT can be thought of as valuation peers to SNY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Latest SNY News From Around the Web
Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.
Global Antibody Production Services Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Roche, Johnson & Johnson, Merck, Novartis, AbbVie, Amgen, Pfizer, Bayer, Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Biogen, AstraZeneca, Sanofi, Alexion Pharmaceuticals, Seattle GeneticsThe report on Global Antibody Production Services Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic [] |
Global Edible Vaccine Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: GSK, Merial, Sanofi, Merck, Ceva, Santa Cruz Animal HealthThe report on Global Edible Vaccine Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition [] |
Global Kidney Disease Drugs Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: GlaxoSmithKline, AbbVie, Pfizer, Sanofi, Kissei Pharmaceutical, Roche, Teva Pharmaceutical Industries, Keryx Biopharmaceuticals, AstraZeneca, Amgen, Changxing Pharmaceutical, Tianjin Tongrentang Group, zhejiang Shengbokang Pharmaceutical, Hebei Ruisen Pharmaceutical, Jiangxi Jimin Kexin JThe report on Global Kidney Disease Drugs Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic [] |
Global H1N1 Vaccines Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Abbott, Cipla, GSK, Baxter International, Hualan Biological Engineering, Sanofi, Sinovac Biotech, Mitsubishi Tanabe Pharma, Pfizer, MerckThe report on Global H1N1 Vaccines Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition [] |
Global Overactive Bladder (OAB) Therapeutics Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical IndustriesThe report on Global Overactive Bladder (OAB) Therapeutics Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a [] |
SNY Price Returns
| 1-mo | -0.88% |
| 3-mo | 3.04% |
| 6-mo | 7.30% |
| 1-year | 4.11% |
| 3-year | 35.13% |
| 5-year | 46.21% |
| YTD | 9.59% |
| 2020 | -0.83% |
| 2019 | 23.73% |
| 2018 | 4.20% |
| 2017 | 8.73% |
| 2016 | -2.52% |
SNY Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching SNY
Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...